The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| AQST | +24.82% | +30.04% | +5.39% | -56% |
| S&P | +16.9% | +95.99% | +14.39% | +139% |
Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.
A decision on a crucial regulatory filing is being delayed indefinitely.
These pharma stocks are undervalued, and could be solid picks over the long term.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $10.00M | -50.2% |
| Gross Profit | $5.44M | -65.1% |
| Gross Margin | 54.40% | -23.1% |
| Market Cap | $328.78M | 38.9% |
| Market Cap / Employee | $2.32M | 0.0% |
| Employees | 142 | 5.2% |
| Net Income | -$13.55M | -393.6% |
| EBITDA | -$11.23M | -4418.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $60.54M | -32.6% |
| Accounts Receivable | $9.65M | 123.0% |
| Inventory | 8.1 | 16.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $121.15M | 5.0% |
| Short Term Debt | $5.11M | 245.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -61.56% | -32.1% |
| Return On Invested Capital | -7.74% | 9.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$8.02M | -13.9% |
| Operating Free Cash Flow | -$7.91M | -13.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -10.00 | -7.15 | -4.41 | -5.40 | -16.74% |
| Price to Sales | 7.70 | 5.64 | 5.11 | 7.45 | 83.93% |
| Price to Tangible Book Value | -10.00 | -7.15 | -4.41 | -5.40 | -13.90% |
| Enterprise Value to EBITDA | -60.89 | -27.92 | -17.31 | -35.13 | -103.47% |
| Total Debt | $119.43M | $121.94M | $124.56M | $126.26M | 8.02% |
AQST earnings call for the period ending June 30, 2022.
AQST earnings call for the period ending March 31, 2022.
AQST earnings call for the period ending December 31, 2021.
AQST earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
